Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION: Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
NCT04064346Phase 3Terminated
- Sponsor
- Palladio Biosciences
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Palladio Biosciences. Started Oct 2021; status: terminated.
02
Drugs
lixivaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT04064346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064346.